Although synovitis is the pathological hallmark of rheumatoid arthritis (RA), many extra-
articular manifestations (EMs) and comorbidities likely occur due to the complex, chronic …

Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are closely related conditions
characterized by systemic inflammation, a predominant IL-6 signature, an excellent …

Background More than half of patients with polymyalgia rheumatica have a relapse during
tapering of glucocorticoid therapy. Previous studies have suggested that interleukin-6 …

Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several
cancers. While these immunotherapies have improved patient outcomes in many clinical …

Importance Few treatments are available for patients with glucocorticoid-dependent
polymyalgia rheumatica. IL-6 antagonists may reduce disease activity in patients with active …

Importance Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are related
inflammatory disorders occurring in persons aged 50 years and older. Diagnostic and …

GCA and PMR are conditions of older persons that frequently overlap. The traditional
concept of GCA has focused on cranial symptoms such as headache and visual …

Rheumatologists face unique challenges in discriminating between rheumatologic and
nonrheumatologic disorders with similar manifestations, and in discriminating among …

Background Giant cell arteritis (GCA; sometimes referred to as temporal arteritis) and
polymyalgia rheumatica (PMR) are common and interrelated inflammatory conditions that …

Therapy for polymyalgia rheumatica (PMR) varies widely in clinical practice as international
recommendations for PMR treatment are not currently available. In this paper, we report the …